THE GRANITE GROUP REOPENS ITS NEWLY REMODELED SINK & SPOUT SHOWROOM IN MANCHESTER, NH
'Everywhere you look, you find another great idea!'
Sink & Spout Manchester, NH
Sink & Spout Manchester, NH
Concord, NH, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Sink & Spout, The Granite Group's retail showroom division, has announced the reopening of its showroom in Manchester, NH.
Located off Exit 6 on Route 293, next to the Amoskeag Circle, the Manchester Sink & Spout now offers a new space built to inspire bath, kitchen, and lighting selections that fit every style and budget.
Once in the showroom, the Sink & Spout sales team helps customers explore a wide array of tubs, vanities, showers, sinks, faucets, lighting, and more from Kohler, House of Rohl, Perrin & Rowe, Brizo, Bertch, Hinkley, BainUltra, and many other brands.
Everywhere you look inside the newly remodeled showroom, you will also see dozens of styles of indoor and outdoor lights. 'Often lighting is an afterthought,' shared Sink & Spout Senior Sales Associate Danielle Gagne, 'and we like to help people think of lighting as an integral part of their project. When this happens, it opens up opportunities to match finishes or coordinate with the style they've chosen for their bath or kitchen fixtures.'
For fans of the television show 'Dream Home Makeover,' Sink & Spout offers a unique opportunity to add a little 'Studio McGee' to a customer's home in an affordable way. 'We were one of the first companies in New England to offer a full selection of Kohler x Studio McGee bath, kitchen, and lighting fixtures,' explains Sink & Spout Showroom Sales Director Dan Lorenz. 'Our showroom team can help guide you to Shea McGee's Malin or Seagrove vanity options, as well as her Edalyn kitchen faucet that pairs perfectly with many sinks, including Kohler's Ironridge® design.'
The new Manchester showroom is a place to browse and gather ideas while in the 'dreaming phase' of a project, and when the time is right, it's also an ideal resource for customers ready to consult with a person who has the expertise necessary to answer questions that will help guide them to the best options for their family's needs. 'We don't believe in high-pressure selling techniques,' explains Lorenz. 'We work much better in partnership with our customers. Our team will be there with you during every step and work with your contractor to help make your delivery and installation go smoothly.'
Click here for Manchester showroom hours, directions, and phone number
About The Granite GroupHeadquartered in Concord, NH, The Granite Group distributes plumbing, heating, cooling, piping, water systems, and energy products to contractors and fuel dealers across New England through 68 wholesale branches and a best-in-class online store. The company also operates 17 retail showrooms under the Sink & Spout name, offering an expertly trained staff and an extensive array of bath, kitchen, and lighting products. Founded in 1971 in Worcester, MA, The Granite Group celebrated its 50th anniversary in 2021 alongside the exceptional people who have driven its success. Of all the recognition The Granite Group has received as a business, the workplace awards are the ones for which the company is most proud. For more information, visit thegranitegroup.com.
Attachments
Sink & Spout Manchester, NH
Sink & Spout Manchester, NH
CONTACT: Brad Dupuis The Granite Group (603) 545-3335 bdupuis@thegranitegroup.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
Biovica Signs Agreement with Fifth Tier-1 US Biopharma Company
UPPSALA, SE / / June 11, 2025 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, active in blood-based cancer monitoring, has signed a new Master Service Agreement (MSA) - along with an initial Work Order of ~800 kSEK - with a Tier-1 US-based biopharmaceutical company. The new customer, a global leader in oncology drug development, becomes the fifth Tier-1 US biopharma company to join Biovica's Pharma Services customer base. The agreement covers testing of Phase 1 clinical trial samples in support of the development of next-generation CDK4/6 inhibitors and is a pilot study with DiviTum® TKa. " This marks a milestone in our growing customer base, highlighting the increasing relevance of Biovica's TKa biomarker assay in advanced cancer therapy development. It demonstrates the strong and growing recognition of the value our assay brings to the development of next-generation oncology treatments that ultimately benefit cancer patients. ," said Anders Rylander, CEO of Biovica. Contact Anders Rylander, CEOPhone: +46 76 666 16 47E-mail: Anders Morén, CFOPhone: +46 73 125 92 46E-mail: Biovica - Treatment decisions with greater confidence Biovica develops and commercializes blood-based biomarker assays that help oncologists monitor cancer progression. Biovica's assay, DiviTum® TKa, measures cell proliferation by detecting the TKa biomarker in the bloodstream. The assay has demonstrated its ability to provide insight to therapy effectiveness in several clinical trials. The first application for the DiviTum® TKa test is treatment monitoring of patients with metastatic breast cancer. Biovica's vision is: "Improved care for cancer patients." Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum® TKa has received FDA 510(k) clearance in the US and is CE-marked in the EU. Biovica's shares are traded on the Nasdaq First North Premier Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser. For more information, please visit: Attachments Biovica signs agreement with fifth Tier-1 US biopharma company SOURCE: Biovica International View the original press release on ACCESS Newswire Sign in to access your portfolio
Yahoo
3 hours ago
- Yahoo
MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies
MaxCyte and Ori Biotech successfully integrate their ExPERT™ and IRO® platforms to improve the yield of gene-edited T cells and shorten manufacturing timelines ROCKVILLE, Md. and LONDON, June 11, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, and Oribiotech Ltd. (Ori), a leader in advanced cell and gene therapy (CGT) manufacturing technology, today announced a strategic collaboration aimed at enhancing efficiency, scalability, and productivity in cell therapy manufacturing. This collaboration combines the MaxCyte ExPERT™ platform and proven Flow Electroporation® technology, widely recognized for its efficient and scalable transfection capabilities, utilized in over 19 active clinical and commercial programs, with Ori's innovative next-generation cell therapy manufacturing platform, IRO® (ee-RO). The collaboration will specifically evaluate how the IRO platform can optimize the yield and streamline the manufacturing timelines of MaxCyte-engineered primary T cells compared to traditional post-electroporation cell expansion processes. As a key component of this joint effort, Ori and MaxCyte have selected CD19 CAR expression via CRISPR knock-in in activated T cells as the test system for initial evaluation. MaxCyte's technology offers unparalleled flexibility and efficiency in transfecting cells at clinical scale, seamlessly integrating with diverse upstream and downstream processes within cell therapy workflows. The IRO platform complements this by introducing automated fluid handling, customizable mixing, and the OriConnect® tubeless sterile connection system, enhancing cell culture efficiency and scalability. Together, these complementary technologies provide therapy developers with a powerful toolkit to achieve clinically relevant quantities of gene-edited T cells more rapidly and efficiently. Maher Masoud, President and CEO of MaxCyte, commented, 'We are excited to collaborate with the team at Ori Biotech, combining our respective strengths and innovative technologies to significantly enhance manufacturing processes. This partnership underscores our commitment to enabling therapy developers to more effectively address the evolving demands of cell therapy manufacturing, ultimately accelerating the availability of transformative treatments for patients.''Our partnership with MaxCyte is another example of Ori's dedication to providing flexible and scalable solutions that address critical challenges in cell and gene therapy manufacturing,' said Jason C. Foster, CEO of Ori Biotech. 'By integrating modular, best-of-breed technologies, we're raising the standard of manufacturing by enhancing commercial viability. Ultimately, this collaboration helps bring cell therapies to patients faster, more reliably, and at greater scale.' Through their shared commitment to innovation and industry collaboration, MaxCyte and Ori Biotech are enabling developers of advanced therapies to adopt integrated, best-of-breed solutions, accelerating the path from research to commercialization and making next-generation treatments more accessible to patients globally. About MaxCyte At MaxCyte®, we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation® technology and SeQure DX™ gene editing risk assessment services enable precise, efficient and scalable cell engineering. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers from around the world to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we've been advancing cell engineering, shaping the future of medicine. Learn more at and follow us on X and LinkedIn. About Ori Biotech Ori Biotech is a London and Philadelphia-based manufacturing technology company on a mission to enable widespread patient access to life-saving cell and gene therapies. IRO®, Ori's next-generation manufacturing platform automates better biology, accelerates product development and enables therapy developers to scale their products' clinical and commercial impact by seamlessly transitioning from R&D to GMP on one platform. The promise of the innovative Ori platform is to automate cell therapy manufacturing, increasing throughput, improving quality and decreasing costs by combining proprietary hardware, consumables, software, data and analytics. For news and updates, visit Forward Looking Statements This press release contains forward-looking statements within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the anticipated benefits, outcomes, and impact of the collaboration between MaxCyte and Ori Biotech; the potential for improving clinical success and commercial viability through new manufacturing standards; and the intention to accelerate development timelines, increase access to next-generation cell therapies, and deliver transformative treatments to patients globally. These statements are based on current expectations, estimates, forecasts, and projections about the industry and markets in which MaxCyte operates, as well as management's current beliefs and assumptions. Words such as 'aims,' 'expects,' 'anticipates,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' 'may,' 'will,' 'should,' 'continue,' and variations of such words and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and involve certain risks, uncertainties, and assumptions that are difficult to predict and are often beyond the control of the companies involved. Actual outcomes and results may differ materially from those expressed or implied in these forward-looking statements due to various factors, including changes in market conditions, technological advancements, regulatory developments, and the success of ongoing research and evaluation efforts. Risks and uncertainties related to our business are described in greater detail in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission ('SEC') on March 11, 2025, as well as in discussions of potential risks, uncertainties, and other important factors in the other filings that we make with the Securities and Exchange Commission from time to time, including in our Form 10-Q for the quarter ended May 8, 2025. These documents are available through the Investor Menu, Financials section, under 'SEC Filings' on the Investors page of our website at Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Except as required by law, MaxCyte does not undertake any obligation to update or revise any forward-looking statements to reflect new information, events, or circumstances after the date of this release. MaxCyte Contacts: US IR AdviserGilmartin GroupDavid Deuchler, CFA+1 415-937-5400ir@ Oak Street CommunicationsKristen Whitekristen@ Nominated Adviser and Joint Corporate BrokerPanmure LiberumEmma Earl / Freddy CrossleyCorporate BrokingRupert Dearden+44 (0)20 7886 2500 UK IR AdviserICR HealthcareMary-Jane ElliottChris Welsh+44 (0)203 709 5700maxcyte@ Ori Biotech Contact: Debby Betzmedia@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Hypebeast
5 hours ago
- Hypebeast
ASICS GT-2160 'Black/Morpho' Delivers Bold Contrast and Retro Appeal
Name:ASICS GT-2160 'Black/Morpho'Colorway:'Black/Morpho'SKU:1203A275-003MSRP:$130 USDRelease Date:Available NowWhere to Buy:ASICS TheASICSGT-2160receives a vibrant and intriguing addition with its new 'Black/Morpho' colorway. This iteration continues to pay homage to the technical design language of the GT-2000 series from the early 2010s, while its colorway draws inspiration from the striking black morpho tetra fish. The silhouette combines a stealthy black mesh upper with vivid green and blue overlays, creating a bold visual contrast that highlights the shoe's intricate details. Metallic silver elements are strategically incorporated into the design, further elevating the visual appeal, all sitting atop an off-white sole unit that completes the dynamic look. Emblematic features from the GT-2000 are also carried over, including a segmented midsole structure and visible GEL® technology inserts. This combination not only creates an industrial aesthetic but also provides advanced cushioning properties, enhancing comfort.
